Last reviewed · How we verify
Pneumococcal Conjugate Vaccine formulation 2
At a glance
| Generic name | Pneumococcal Conjugate Vaccine formulation 2 |
|---|---|
| Also known as | SP0202-VI |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (PHASE2)
- A Study of V118E in Healthy Participants (V118E-003) (PHASE1)
- Clinical Trial of PCV24 in Children Aged 2-17 Years (PHASE1)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001) (PHASE1)
- Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years (PHASE1)
- Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE2)
- A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |